==== Front BMC Cardiovasc Disord BMC Cardiovasc Disord BMC Cardiovascular Disorders 1471-2261 BioMed Central London 37386358 3282 10.1186/s12872-023-03282-z Research Additive effect between homocysteine and low-density-lipoprotein cholesterol upon incidence of novel carotid plaque formation: data from a Chinese community-based cohort Momin Mohetaboer muhtebar@hotmail.com 1 Fan Fangfang fang9020@126.com 12 Yang Ying yangying1527@163.com 13 Li Jianping lijianping03455@pkufh.com 1 Jia Jia jiajia9985@163.com 12 Zhang Yan drzhy1108@163.com 12 1 grid.411472.5 0000 0004 1764 1621 Department of Cardiology, Peking University First Hospital, 8thXishiku Road, Beijing, 10003 China 2 grid.411472.5 0000 0004 1764 1621 Institute of Cardiovascular Disease, Peking University First Hospital, Beijing, China 3 grid.411472.5 0000 0004 1764 1621 Echocardiography Core Lab, Institute of Cardiovascular Disease at Peking University First Hospital, Beijing, China 30 6 2023 30 6 2023 2023 23 3328 8 2022 7 5 2023 © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Objective Homocysteine (HCY) has been associated with carotid plaque in cross-sectional studies, but the prospective relationship between HCY and incident carotid plaque has not been well established. The purpose of this study was to investigate the association between HCY and incidence of novel carotid plaque in a Chinese community-based population without pre-existing carotid atherosclerosis and to assess the additive effect of HCY and low-density lipoprotein cholesterol (LDL-C) on the incidence of novel plaque. Methods: At baseline, we measured HCY and other risk factors in subjects aged ≥ 40 years. All participants underwent carotid ultrasound examinations at baseline and after an average of 6.8 years of follow-up. Incidence of plaque was identified if plaque was absent at baseline, but plaque was detected at the end of follow-up. A total of 474 subjects were included in the analysis. Results: The incidence of novel carotid plaque was 24.47%. Multivariate regression analyses showed that HCY was independently associated with a 1.05-fold-higher likelihood for incident novel plaque (adjusted odds ratio [OR] = 1.05, 95% confidence interval [CI]: 1.01–1.09, P = 0.008). Using tertile 1 and tertile 2 for reference, the top HCY tertile (T3) showed a 2.28-fold-higher likelihood for incident plaque (adjusted OR = 2.28, 95%CI: 1.33–3.93, P = 0.002). The combination of HCY T3 and LDL-C ≥ 3.4 mmol/L had the highest risk for novel plaque formation (adjusted OR = 3.63, 95%CI: 1.67–7.85, P = 0.001) compared to those without either condition. In the LDL-C ≥ 3.4 mmol/L subgroup, HCY was significantly associated with incidence of plaque (adjusted OR = 1.16, 95%CI: 1.04–1.28, P = 0.005, P-interaction = 0.023). Conclusion: In the Chinese community-based population, HCY was independently associated with the incidence of novel carotid plaque. There were additive effect between HCY and LDL-C on the incidence of plaque, the highest risk was observed in individuals with both high HCY levels and LDL-C ≥ 3.4 mmol/L. Our findings suggest that HCY may be a potential target for preventing the incidence of carotid plaque, particularly in individuals with elevated LDL-C levels. Keywords Homocysteine Carotid plaque LDL-C Atherosclerosis UMHS-PUHSC Joint Institute for Translational and Clinical ResearchBMU20110177B, MU20160530 BMU20110177B, MU20160530 BMU20110177B, MU20160530 BMU20110177B, MU20160530 BMU20110177B, MU20160530 BMU20110177B, MU20160530 Momin Mohetaboer Fan Fangfang Yang Ying Li Jianping Jia Jia Zhang Yan Capital’s Funds for Health Improvement and Research2020-2-2053 2020-2-2053 2020-2-2053 2020-2-2053 2020-2-2053 2020-2-2053 Momin Mohetaboer Fan Fangfang Yang Ying Li Jianping Jia Jia Zhang Yan Chinese Cardiovascular Association-Access fund2019-CCA-ACCESS-112 2019-CCA-ACCESS-112 2019-CCA-ACCESS-112 2019-CCA-ACCESS-112 2019-CCA-ACCESS-112 2019-CCA-ACCESS-112 Momin Mohetaboer Fan Fangfang Yang Ying Li Jianping Jia Jia Zhang Yan Chinese National Natural Science Foundation81703288 81703288 81703288 81703288 81703288 Momin Mohetaboer Fan Fangfang Yang Ying Li Jianping Zhang Yan issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2023 ==== Body pmcBackground and aims Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality globally. Novel carotid plaque formation is considered a marker of future carotid atherosclerotic disease and a well-accepted surrogate endpoint for ischemic stroke [1]. While traditional risk factors play a role in predicting atherosclerotic carotid disease [2–7], some well-established biomarkers, such as inflammatory, metabolic, endothelial, hematologic, lipids, and thrombosis-related biomarkers [8, 9], may also help in predicting the risk of atherosclerotic carotid disease. Low-density lipoprotein cholesterol (LDL-C) is proven to elevate ASCVD risk. However, some patients remain at significantly high residual risk despite intensive statin therapy [10]. Homocysteine (HCY) is well-documented as a biomarker for ASCVD [11]. Worth mentioning is that hyperhomocysteinemia (HHCY) is accounted for an increased risk of ischemic stroke in hypertension patients in China [12]. Studies have shown that HHCY was associated with carotid plaque presence, burden, instability, morphology, and total carotid plaque area (TPA) measured by Doppler ultrasound examination [13–15], as well as restenosis after carotid endarterectomy [7]. However, most of the prior studies regarding the association between HCY and carotid atherosclerosis were cross-sectional studies. Prospective data on HCY predicting plaque development in general populations were very scarce. and the cellular and molecular mechanisms linking HCY and atherosclerosis are not fully understood, which include oxidative stress, inflammation, DNA hypomethylation, endoplasmic reticulum stress, and mitochondrial dysfunction [16]. Previous studies also established a possible link between HHCY, dyslipidemia and atherosclerosis. An inverse association between HCY and high-density lipoprotein cholesterol (HDL-C) has been described in human and animal models of HHCY [17, 18]. Few studies showed that HHCY could accelerate atherosclerosis when associated with elevated plasma lipids [19]. However, the mechanisms linking HCY and lipid metabolism were not thoroughly investigated. This study aims to investigate whether HCY is associated with future novel carotid plaque formation in Chinese community subjects without pre-existing carotid atherosclerosis. The study also aims to assess the additive effect between HCY and LDL-C on the incidence of novel carotid plaque. These findings may help in identifying individuals at higher risk of developing atherosclerotic carotid disease and inform the development of targeted prevention and treatment strategies. Methods Subjects We enrolled subjects from a cohort in the Gucheng and Pingguoyuan communities of Shijingshan District in Beijing, China. At baseline (from December 2011 to April 2012), we measured HCY and other risk factors in subjects aged ≥ 40 years. All participants underwent carotid ultrasound examinations at baseline and after an average of 6.8 years of follow-up (from May 2018 to July 2018). The methods and preliminary results of this survey have been reported elsewhere [20, 21]. In brief, 708 participants with available data and quantitative carotid artery measurements for both baseline and follow-up were enrolled. Subjects at baseline with carotid plaques and CVD (self-reported coronary heart disease, stroke, or previous transient ischemic attack) were excluded. Finally, a total of 474 subjects were ultimately included in our analysis. This study was approved by Peking University First Hospital ethics committee. The procedures followed institutional guidelines and the Declaration of Helsinki principles, and each participant provided written informed consent. Measurements and definitions of the baseline data We used a standardized questionnaire to interview participants to collect information, including their sociodemographic status, medical history, past and current medication use, and personal habits such as cigarette and alcohol consumption. We obtained a venous blood sample from every participant’s forearm after at least 12 h of overnight fast. These samples were used to measure the total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), fasting blood glucose (FBG), and the serum creatine (SCR) level. A Cobas 8000 modular analyzer (Roche Diagnostics, Indianapolis, IN, USA) was used for all laboratory variable measurements at baseline in the Peoples Liberation Army General Hospital laboratory. The estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI equation. The peripheral blood pressure was measured using the standard method, and we used the average of three measurements. Hypertension was defined as self-reported hypertension history, or systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg or taking anti-hypertensive medicine. Diabetes mellitus was defined as self-reported diabetes history, or FBG level ≥ 7.0 mmol/L, or OGTT value ≥ 11.1 mmol/L, or taking anti-diabetic medicine. Dyslipidemia was defined as any self-reported history of hyperlipidemia, or TG level ≥ 1.70 mmol/L, or TC level ≥ 5.18 mmol/L, or LDL-C level ≥ 3.4 mmol/L, or HDL-C level < 1.04 mmol/L, or taking lipid-lowering medicine, according to the China Adult Dyslipidemia Prevention Guide (2007 Edition) criteria [22]. Current alcohol drinking was defined as drinking at least once per week for at least half a year, and current smoking was defined as smoking at least one cigarette per day for at least half a year. body mass index (BMI) was calculated using weight (kg) divided by height (m) squared. Current medication information for vitamin B supplements, antihypertension drug, anti-diabetic drug and lipid-lowering drug use were collected. The methods and relevant results of this data have been reported elsewhere [23, 24]. Carotid ultrasonography measurement and definition for carotid plaque All participants underwent carotid ultrasound examinations at baseline and after 6.8 years of follow-up. We used GE Vivid ultrasound system (GE Medical Systems, Milwaukee, WI, USA) equipped with an 8-MHz linear array vascular probe. Carotid ultrasounds were performed by the standard protocols according to Mannheim carotid intima-media thickness (CIMT) and Plaque Consensus [25]. The subjects were supine, with their head turned slightly away from the probe. We scanned the far wall and the near wall of the right and left common carotid artery, the bifurcation (bulb) and the internal carotid artery for the presence of plaques. A carotid plaque was defined using the Mannheim standard, as focal structures encroaching into the arterial lumen at least 0.5 mm or 50% of the surrounding IMT value or demonstrating a thickness > 1.5 mm as measured from the intima-lumen interface to the media-adventitia interface [25]. Certified sonographers performed carotid ultrasonography and judged the presence of a plaque. Incidence of plaque was identified if plaque was absent at baseline, but plaque was detected at the end of the study follow-up. The methods and relevant results of this data have been reported elsewhere [21]. Statistical analysis Categorical variables were presented by numbers and percentages. Continuous variables were described by using means plus standard deviations and medians for normally distributed data and non-normally distributed data, respectively. We conducted univariate comparisons between groups by using ANOVA for continuous variables and the χ2 test for categorical variables. We performed both univariate and multivariate logistic regression analyses to determine the relationships between HCY categories and the incidence of novel carotid plaque. We adjusted confounding variables in regression analysis, including age, gender, smoking, alcohol drinking, BMI, eGFR, TC, LDL-C, HDL-C, hypertension, diabetes, vitamin B supplements, antihypertension drug use, anti-diabetic drug use and lipid-lowering drug use (definitions mentioned above). Generalized additive model (GAM) with a spline smoothing curve was applied to inspect the relationship between the incidence of plaque and HCY, and a piecewise linear regression analysis was conducted to fit the smoothing curve. Stratification analysis and interaction terms were used to investigate whether the association between HCY and incident plaque differed according to LDL-C. Analyses were performed using Empower® (www.empowerstats.com, X&Y solutions, Inc., Boston, MA, USA) and R (http://www.R-project.org). P < 0.05 was considered statistically significant. Results Baseline characteristics of the study participants In this study, 474 Chinese participants without carotid plaque at baseline were included. As Table 1 showed, the mean age of the participants was 51.36 ± 4.81 years, and 28.69% were male. The median level of HCY was 11.22 μmol/L. After an average follow-up period of 6.8 years, 116 of the participants developed carotid plaques, resulting in an incidence of 24.47%. The baseline characteristics of the novel plaque group were compared with those of the no plaque group, and significant differences were observed. The novel plaque group was found to be older, more likely to be male, and had lower eGFR and HDL-C levels. The prevalence rates of smoking, alcohol drinking, diabetes, and dyslipidemia were also higher in the novel plaque group. Importantly, the novel plaque group had a higher level of HCY (12.42 μmol/L vs. 10.94 μmol/L, P < 0.001) compared to the no plaque group.Table 1 A comparison of the baseline characteristics of participants between Novel plaque group and No plaque group No plaque (N = 358) Novel plaque (N = 116) P value Age(year-old), mean ± SD 50.86 ± 4.72 52.92 ± 4.75 < 0.001 Sex, N (%) 0.011  male 922 (25.70%) 44 (37.93%)  famale 266 (74.30%) 72 (62.07%)  eGFR(ml/min), mean ± SD 100.57 ± 9.12 97.80 ± 11.30 0.008  BMI (kg/m2), mean ± SD 25.78 ± 3.45 25.96 ± 3.08 0.616  TC (mmol/L), mean ± SD 5.27 ± 0.86 5.32 ± 1.05 0.655  LDL-C (mmol/L), mean ± SD 3.19 ± 0.69 3.29 ± 0.92 0.261  HDL-C (mmol/L), mean ± SD 1.50 ± 0.40 1.41 ± 0.38 0.029  TG (mmol/L), median(Q1-Q3) 1.17 (0.85–1.75) 1.42 (1.01–1.95) 0.264  SBP (mmHg), mean ± SD 127.92 ± 13.80 128.85 ± 14.86 0.594  DBP (mmHg), mean ± SD 75.42 ± 9.53 75.31 ± 8.99 0.915  FBG(mmol/L), mean ± SD 5.84 ± 1.33 5.96 ± 1.26 0.388  HCY(μmol/L), median(Q1-Q3) 10.94 (9.25–13.01) 12.42 (9.71–15.42) < 0.001  Smoking, N (%) 48 (13.41%) 30 (25.86%) 0.002  Drinking, N (%) 76 (21.23%) 35 (30.17%) 0.048  Hypertension, N (%) 99 (27.65%) 35 (30.17%) 0.601  Diabetes, N (%) 41 (11.45%) 22 (18.97%) 0.038  Dyslipidemia, N (%) 232 (64.80%) 90 (77.59%) 0.010  Anti-hypertension drugs, N (%) 54 (15.25%) 18 (15.52%) 0.946  Anti-diabetic drugs, N (%) 20 (5.59%) 8 (6.96%) 0.588  Lipid-lowering drugs, N (%) 21 (5.95%) 10 (8.62%) 0.315  Vitamin B supplement, N (%) 23 (6.42%) 11 (9.48%) 0.267 The smooth curve of the relationship between HCY and carotid plaque formation risk Figure 1 was the result of a generalized additive model (GAM) with a spline smoothing curve, which was applied to inspect the relationship between the incidence of plaque and HCY. The horizontal axis means the values of HCY, and the vertical axis means the predicted risk for novel carotid plaque. A higher HCY corresponded to a higher risk for novel carotid plaque formation after adjusting for age, gender, smoking, alcohol drinking, BMI, eGFR, TG, LDL-C, HDL-C, hypertension, diabetes, vitamin B supplement, antihypertension drug use, anti-diabetic drug use and lipid-lowering drug use. The dotted lines are the 95% confidence interval of the risk values.Fig. 1 The smooth curve of the relationship between HCY and risk for novel carotid plaque formation. Adjusted for: age, gender, smoking, alcohol drinking, BMI, eGFR, TG, LDL-C, HDL-C, hypertension, diabetes, vitamin B supplement, antihypertension drug use, anti-diabetic drug use and lipid-lowering drug use Univariate and multivariate regression analyses for HCY and incidence of novel carotid plaque Univariate and multivariate regression analyses were conducted to investigate the potential independent association between baseline HCY and the incidence of novel carotid plaque. The results, which are presented in Table 2 using HCY levels and tertiles, were adjusted for several potential confounding factors, including age, gender, smoking, alcohol drinking, BMI, eGFR, TG, LDL-C, HDL-C, hypertension, diabetes, vitamin B supplement, antihypertension drug use, anti-diabetic drug use and lipid-lowering drug use. After controlling for these covariates, the odds ratios (ORs) for the incidence of novel carotid plaque increased with increasing HCY levels. Higher HCY was independently associated with a 1.05-fold increase in the likelihood of incident novel plaque (adjusted OR = 1.05, 95% confidence interval [CI]: 1.01–1.09, P = 0.008). When individuals in the top tertile of HCY (T3) were compared to those in the reference tertiles 1 and 2 (T1 + T2), they showed a 2.28-fold higher likelihood of developing novel carotid plaque (adjusted OR = 2.28, 95%CI: 1.33–3.93, P = 0.002).Table 2 Univariate and multivariate regression analysis of the relationship between HCY category and incidence of novel carotid plaque Incidence, n(%) Crude analysis Multivariate analysis OR (95%CI) P OR (95%CI) P HCY(μmol/L) 116 (24.5) 1.06 (1.03–1.09) < 0.001 1.05 (1.01–1.09) 0.008 HCY Tertile  T1(5.72–9.91) 32 (20.3) 1 - 1 -  T2(9.93–12.54) 28 (17.8) 0.85 (0.49–1.50) 0.585 0.81 (0.43–1.51) 0.506  T3(12.56–50.64) 56 (35.2) 2.14 (1.29–3.55) 0.003 2.00 (1.03–3.89) 0.040  T1-T2(5.72–12.54) 60 (19.1) 1 - 1 -  T3(12.56–50.64) 56 (35.2) 2.31 (1.50–3.55) < 0.001 2.28 (1.33 -3.93) 0.002 Adjusted for: age, gender, smoking, alcohol drinking, BMI, eGFR, TG, LDL-C, HDL-C, hypertension, diabetes, vitamin B supplement, antihypertension drug use, anti-diabetic drug use and lipid-lowering drug use Additive effect and interaction analysis between HCY and LDL-C on the incidence of novel carotid plaque Table 3 presents the results of the analysis that examined the joint effect of HCY and LDL-C on the occurrence of novel plaque. The analysis was adjusted for potential confounding variables, including age, gender, smoking, alcohol drinking, BMI, eGFR, TG, LDL-C, HDL-C, hypertension, diabetes, vitamin B supplement, antihypertension drug use, anti-diabetic drug use and lipid-lowering drug use. The study created four new categories based on the combination of HCY and LDL-C levels, including Group 1 (HCY < T3 and LDL-C < 3.4 mmol/L), Group 2 (HCY < T3 and LDL-C ≥ 3.4 mmol/L), Group 3 (HCY ≥ T3 and LDL-C < 3.4 mmol/L), and Group 4 (HCY ≥ T3 and LDL-C ≥ 3.4 mmol/L). The results indicated that participants with both elevated HCY and LDL-C (Group 4) had a 3.63-fold higher risk of developing novel plaque compared to those in Group 1 (adjusted odds ratio (OR) = 3.63, 95% confidence interval (CI): 1.67–7.85, P = 0.001). Furthermore, individuals with elevated HCY and normal LDL-C (Group 3) were 2.15 times more likely to develop novel plaque compared to those without either condition (adjusted OR = 2.15, 95%CI: 1.10–4.18, P = 0.025). In contrast, those with high LDL-C but normal HCY (Group 2) did not significantly affect the likelihood of developing novel plaque (P < 0.05) compared to Group 1.Table 3 Additive Effect analysis between HCY and LDL-C on incidence of novel carotid plaque Crude analysis Multivariate analysis OR (95%CI) P OR (95%CI) P Group 1 HCY < T3 and LDL-C < 3.4 mmol/L 1.0 - 1.0 - Group 2 HCY < T3 and LDL-C ≥ 3.4 mmol/L 1.52 (0.86–2.70) 0.152 1.51 (0.82–2.77) 0.186 Group 3 HCY ≥ T3 and LDL-C< 3.4 mmol/L 2.53 (1.46–4.38) 0.001 2.15 (1.10–4.18) 0.025 Group 4 HCY ≥ T3 and LDL-C ≥ 3.4 mmol/L 3.42 (1.73–6.75) < 0.001 3.63 (1.67–7.85) 0.001 Adjusted for: age, gender, smoking, alcohol drinking, BMI, eGFR, TG, HDL-C, hypertension, diabetes, vitamin B supplement, antihypertension drug use, anti-diabetic drug use and lipid-lowering drug use Table 4 presents the results of the analysis that explored the additive effect and interaction between HCY and LDL-C on the incidence of plaque. Specifically, the analysis examined the association between HCY and plaque incidence in the subgroup of participants with LDL-C ≥ 3.4 mmol/L. The results showed that HCY was significantly associated with the incidence of plaque in this subgroup (adjusted OR = 1.16, 95%CI: 1.04–1.28, P = 0.005), and the P-value for interaction was 0.023.Table 4 Interaction analysis between HCY and LDL-C on the incidence of novel carotid plaque HCY LDL < 3.4 mmol/L LDL ≥ 3.4 mmol/L OR (95%CI) P OR (95%CI) P P interaction Crude analysis 1.05 (1.01- 1.08) 0.009 1.12 (1.03, 1.21) 0.006 0.107 Multivariate analysis 1.03 (0.99- 1.07) 0.1632 1.16 (1.04, 1.28) 0.005 0.023 Adjusted for: age, gender, smoking, alcohol drinking, BMI, eGFR, TG, HDL-C, hypertension, diabetes, vitamin B supplement, antihypertension drug use, anti-diabetic drug use and lipid-lowering drug use Discussion The current study aimed to investigate the potential association between HCY levels and the incidence of novel plaque formation in a previously carotid plaque-free population. The findings of this study revealed that HCY was independently associated with the incidence of novel plaque formation, and these associations differed according to LDL-C levels. Specifically, the correlation between HCY and plaque formation was more significant in individuals with high LDL-C and HCY levels. To the best of our knowledge, this is the first prospective study that has examined the relationship between HCY and carotid plaque formation in the general population. Firstly, the results of the current study demonstrated a linear relationship between HCY levels and the incidence of carotid plaque formation. However, statistical significance was observed only in the top tertile of HCY (≥ 12.56umol/L), which may be due to the small sample size. Thus, further research based on a larger sample size is warranted to confirm the results of this study. The relationship between homocysteine (HCY) and atherosclerosis is still a subject of debate in the medical field. Several cross-sectional studies have reported a significant correlation between carotid atherosclerosis and elevated HCY levels, while others have yielded conflicting results. Results from The Cyprus Study found that elevated HCY levels were associated with total plaque thickness in the Middle East population [26]. The CUDAS study showed that HCY was an independent risk factor for increased carotid plaque thickness in a general population from Western Australia [27]. Ryuichi et al. confirmed that the association between HCY and carotid plaque was present in elderly Japanese as well [28]. A study from Southern China revealed that HHCY aggravated instability of carotid plaque and carotid artery stenosis through increasing inflammation [29]. The Northern Manhattan Study also reported an association between elevated HCY and carotid plaque morphology and increased TPA [13]. Moreover, the findings from the Chinese population suggested that HCY was linked to advanced carotid plaque [14]. Results in Japanese showed that higher HCY levels correlated with increased severity of carotid atherosclerotic plaques and prevalence of lacunar infarction [30]. Similar results were found in chronic hemodialysis patients [31] and hypertensive patients [32]. In contrast, numerous cross-sectional studies didn’t find a significant association between HCY and carotid plaque in healthy French volunteers [33], non-insulin-dependent diabetes mellitus subjects [34], Chinese population [35, 36], Spain population [15], and patients with chronic renal failure [37]. Numerous prospective studies have explored the risk factors for carotid plaque progression [2, 4–6]. However, the prognostic role of HCY in carotid plaque remains unclear. Previous cohort studies on HCY and plaque progression in systemic lupus erythematosus patients have demonstrated a positive correlation between high HCY concentrations and atherosclerosis progression [38–40]. However, to our knowledge, this is the first cohort study investigating the association between HCY and plaque progression in the general population, thereby providing valuable evidence to resolve this knowledge gap. Furthermore, our study found additive effect between HCY and LDL-C on the incidence of novel carotid plaque formation. The risk for carotid plaque progression was more significant in those combined HHCY and high LDL-C than either alone. We also analyzed the interaction between HCY and different levels of LDL-C. The additive effect was significant when LDL ≥ 3.4 mmol/L, whereas LDL2.6 ≥ mmol/L was not. Although the cut-off value of LDL-C is different according to individual cardiovascular risk, the results suggested that the combined effect of LDL-C and HCY was significant at a higher LDL-C level. These findings were consistent with previous studies. A study including 12,683 US subjects showed that individuals with elevated HCY and hypercholesterolemia have a higher likelihood to suffer a stroke than those without either condition [41]. W Herrmann et al. revealed that HCY improved the predictive value of LDL-C for coronary disease [19]. Data from a multicenter European case–control study showed that HCY increased the CVD risk associated with hyperlipidemia [42]. A case–control study of Korean men showed that metabolic syndrome with HHCY had a more excellent predicting value for CVD than metabolic syndrome alone [43]. Regarding experimental studies, several findings implied that HHCY enhanced and accelerated atherosclerosis induced by hyperlipidemia [44–46]. The present study has some limitations that need to be acknowledged. Firstly, only a single baseline measurement of plasma HCY was used to predict future cardiovascular events. Subsequent changes in plasma HCY levels were not considered, which may have influenced the results. Secondly, the study sample was relatively small and was recruited from an urban community in northern China, which may limit the generalizability of the findings to other populations. Moreover, other factors that could contribute to plaque progression, such as hsCRP, were not taken into account. Additionally, other indexes of carotid atherosclerosis, including TPA and plaque number, were not analyzed in this study. Despite these limitations, our study provides significant implications for the prevention and assessment of CVD. Specifically, our findings suggest that testing HCY levels, especially in individuals with high LDL-C, is crucial for a comprehensive evaluation of CVD risk. By identifying individuals with elevated HCY levels, appropriate interventions, such as lifestyle modifications and pharmacological therapies, can be initiated to reduce the risk of future cardiovascular events. These findings have important implications for healthcare providers and policymakers, as they highlight the need for targeted screening and prevention strategies to reduce the risk of cardiovascular disease in high-risk populations. Further studies with larger sample sizes and more comprehensive assessments of atherosclerosis are needed to confirm our findings and guide clinical practice. Conclusion In conclusion, this 6.8-year follow-up study showed that HCY was independently associated with novel carotid plaque formation in persons with no plaque at baseline. Combining LDL-C with HHCY increased the predictive strength for novel carotid plaque. The findings of this study suggest that it is crucial to comprehensively screen for HCY in populations with high LDL-C to prevent atherosclerosis. Therefore, interventions targeting HCY levels may be necessary in individuals at risk of developing atherosclerosis. Acknowledgements The authors thank all study team members for their participation. We are incredibly grateful to the site managers of Gucheng and Pingguoyuan Community Health Centers for their supports. Disclosure statement The authors have no conflicts of interest to declare. Authors’ contributions M.M. participated in the design of the study, performed the statistical analysis, and drafted the manuscript. J.J. participated in the epidemiologic survey and the data management. F.F. participated in implementing the investigation, the data analysis, and drafting the manuscript. Y.Y. performed carotid ultrasonography and judged the presence of carotid plaque. JP.L. and Y.Z. conceived the study, participated in its design and coordination and helped to analyze the data and draft the manuscript. All authors read and approved the final manuscript. Funding 1.UMHS-PUHSC Joint Institute for Translational and Clinical Research (grant No: BMU20110177B, MU20160530); 2. Capital’s Funds for Health Improvement and Research (grant No:2020–2-2053); 3. Chinese Cardiovascular Association-Access fund (grant No: 2019-CCA-ACCESS-112); 4. Chinese National Natural Science Foundation (grant No: 81703288); 5. This study was supported by the Key Laboratory of Molecular Cardiovascular Sciences (Peking University), Ministry of Education, the NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, and the Open Project of Key Laboratory of Genomic and Precision Medicine, Chinese Academy of Sciences. Availability of data and materials The datasets used or analyzed during the current study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate This study was approved by the ethics committee of Peking University and Peking University First Hospital, and each participant provided written informed consent before enrollment. We adhered to the principles of the Declaration of Helsinki. The procedures followed were in accordance with institutional guidelines. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. ==== Refs References 1. Naqvi TZ Lee MS Carotid intima-media thickness and plaque in cardiovascular risk assessment JACC Cardiovasc Imaging 2014 7 10 1025 1038 10.1016/j.jcmg.2013.11.014 25051948 2. Sturlaugsdottir R Aspelund T Bjornsdottir G Predictors of carotid plaque progression over a 4-year follow-up in the Reykjavik REFINE-study Atherosclerosis 2018 269 57 62 10.1016/j.atherosclerosis.2017.12.005 29274849 3. van der Meer IM del Sol Iglesias A Hak AE Bots ML Hofman A Witteman JC Risk factors for progression of atherosclerosis measured at multiple sites in the arterial tree: the rotterdam study Stroke 2003 34 10 2374 9 10.1161/01.STR.0000088643.07108.19 12947155 4. Herder M Johnsen SH Arntzen KA Mathiesen EB Risk factors for progression of carotid intima-media thickness and total plaque area: a 13-year follow-up study: the tromso study Stroke 2012 43 7 1818 1823 10.1161/STROKEAHA.111.646596 22550052 5. Molino-Lova R Macchi C Gori AM High sensitivity C-reactive protein predicts the development of new carotid artery plaques in older persons Nutr Metab Cardiovasc Dis 2011 21 10 776 782 10.1016/j.numecd.2010.02.003 20554169 6. Tattersall MC Gassett A Korcarz CE Predictors of carotid thickness and plaque progression during a decade: the Multi-Ethnic Study of Atherosclerosis Stroke 2014 45 11 3257 3262 10.1161/STROKEAHA.114.005669 25213342 7. Bakoyiannis C, Karaolanis G Fau - Moris D, Moris D Fau - Palla V, et al. Homocysteine as a risk factor of restenosis after carotid endarterectomy. International Angiology 2015; 34(2): 166–71. 8. Martinez E Martorell J Riambau V Review of serum biomarkers in carotid atherosclerosis J Vasc Surg 2020 71 1 329 341 10.1016/j.jvs.2019.04.488 31327598 9. Ammirati E Moroni F Norata GD Magnoni M Camici PG Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis Mediators Inflamm 2015 2015 718329 10.1155/2015/718329 25960621 10. Reith C Armitage J Management of residual risk after statin therapy Atherosclerosis 2016 245 161 170 10.1016/j.atherosclerosis.2015.12.018 26722833 11. Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015;14:6.  12. Li J Jiang S Zhang Y H-type hypertension and risk of stroke in chinese adults: A prospective, nested case-control study J Transl Int Med 2015 3 4 171 178 10.1515/jtim-2015-0027 27847909 13. Alsulaimani S Gardener H Elkind MS Cheung K Sacco RL Rundek T Elevated homocysteine and carotid plaque area and densitometry in the Northern Manhattan Study Stroke 2013 44 2 457 461 10.1161/STROKEAHA.112.676155 23287787 14. Yang X Zhou Y Liu C Homocysteine and carotid plaque stability: a cross-sectional study in Chinese adults PLoS ONE 2014 9 4 e94935 10.1371/journal.pone.0094935 24736609 15. Alvarez B Yugueros X Fernandez E Luccini F Gene A Matas M Relationship between plasma homocysteine and the morphological and immunohistochemical study of carotid plaques in patients with carotid stenosis over 70% Ann Vasc Surg 2012 26 4 500 505 10.1016/j.avsg.2011.05.047 22520390 16. Djuric D Jakovljevic V Zivkovic V Srejovic I Homocysteine and homocysteine-related compounds: an overview of the roles in the pathology of the cardiovascular and nervous systems Can J Physiol Pharmacol 2018 96 10 991 1003 10.1139/cjpp-2018-0112 30130426 17. Obeid R Herrmann W Homocysteine and lipids: S-adenosyl methionine as a key intermediate FEBS Lett 2009 583 8 1215 1225 10.1016/j.febslet.2009.03.038 19324042 18. Chernyavskiy I Veeranki S Sen U Tyagi SC Atherogenesis: hyperhomocysteinemia interactions with LDL, macrophage function, paraoxonase 1, and exercise Ann N Y Acad Sci 2016 1363 138 154 10.1111/nyas.13009 26849408 19. Herrmann W Obeid R Hübner U Jouma M Geisel J Homocysteine in relation to C-reactive protein and low-density lipoprotein cholesterol in assessment of cardiovascular risk Cell Mol Biol (Noisy-le-grand) 2004 50 8 895 901 15704253 20. Fan F Qi L Jia J Noninvasive central systolic blood pressure is more strongly related to kidney function decline than peripheral systolic blood pressure in a Chinese community-based population Hypertension 2016 67 6 1166 1172 10.1161/HYPERTENSIONAHA.115.07019 27141056 21. Yang Y Fan F Kou M Brachial-ankle pulse wave velocity is associated with the risk of new carotid plaque formation: data from a Chinese community-based cohort Sci Rep 2018 8 1 7037 10.1038/s41598-018-25579-2 29728607 22. [2016 Chinese guideline for the management of dyslipidemia in adults]. Zhonghua xin xue guan bing za zhi 2016; 44(10): 833–53. 23. Liu M Fan F Liu B Joint effects of plasma homocysteine concentration and traditional cardiovascular risk factors on the risk of new-onset peripheral arterial disease Diabetes Metab Syndr Obes 2020 13 3383 3393 10.2147/DMSO.S267122 33061499 24. Momin M Jia J Fan F Relationship between plasma homocysteine level and lipid profiles in a community-based Chinese population Lipids Health Dis 2017 16 1 54 10.1186/s12944-017-0441-6 28288621 25. Touboul PJ Hennerici MG Meairs S Mannheim carotid intima-media thickness and plaque consensus (2004–2006–2011) Cerebrovasc Dis 2012 34 4 290 296 10.1159/000343145 23128470 26. Panayiotou ANA Griffin M Tyllis T Georgiou N Martin RM Bond D Tziakouri-Shiakalli C Fessas C Deltas C Serum total homocysteine, folate, 5,10-methylenetetrahydrofolate reductase (MTHFR) 677C–>T genotype and subclinical atherosclerosis Expert Opin Ther Targets 2009 13 1 1 11 10.1517/14728220802560281 19063701 27. McQuillan BMBJ Nidorf M Thompson PL Hung J Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The perth Carotid Ultrasound Disease Assessment Study (CUDAS) Circulation 1999 99 18 2383 8 10.1161/01.CIR.99.18.2383 10318658 28. Kawamoto RDT Tokunaga H Association of plasma homocysteine concentrations with carotid atherosclerosis in elderly Japanese Intern Med 2001 40 12 1189 1194 10.2169/internalmedicine.40.1189 11813842 29. Cao L Guo Y Zhu Z Study of the Inflammatory Mechanisms in Hyperhomocysteinemia on Large-Artery Atherosclerosis Based on Hypersensitive C-Reactive Protein-A Study from Southern China J Stroke Cerebrovasc Dis 2019 28 7 1816 1823 10.1016/j.jstrokecerebrovasdis.2019.04.021 31080137 30. Sasaki T Watanabe M Nagai Y Association of plasma homocysteine concentration with atherosclerotic carotid plaques and lacunar infarction Stroke 2002 33 6 1493 1496 10.1161/01.STR.0000016463.01398.D0 12052980 31. Grekas D Economou H Makedou A Association between hyperhomocysteinemia and ultrasonographic atherosclerotic indices of carotid arteries in chronic hemodialysis patients Nephron Clin Pract 2005 101 4 c180 c186 10.1159/000087412 16103723 32. Catena C Colussi G Url-Michitsch M Nait F Sechi LA Subclinical carotid artery disease and plasma homocysteine levels in patients with hypertension J Am Soc Hypertens 2015 9 3 167 175 10.1016/j.jash.2014.12.020 25660367 33. de Bree A Mennen LI Zureik M Homocysteine is not associated with arterial thickness and stiffness in healthy middle-aged French volunteers Int J Cardiol 2006 113 3 332 340 10.1016/j.ijcard.2005.11.045 16364473 34. Mazza AMC Nulli A Marra G Gnasso A Pastore A Federici G Cortese C Lack of association between carotid intima-media thickness and methylenetetrahydrofolate reductase gene polymorphism or serum homocysteine in non-insulin-dependent diabetes mellitus Metabolism 2000 49 6 718 723 10.1053/meta.2000.6254 10877195 35. Liu C Sun X Lin H Association between hyperhomocysteinemia and metabolic syndrome with early carotid artery atherosclerosis: A cross-sectional study in middle-aged Chinese population Nutrition 2018 53 115 119 10.1016/j.nut.2018.02.014 29778949 36. Li Y Wang L Zhang W Fang Y Niu X No association between elevated homocysteine levels and carotid atherosclerosis in a rural population in China Stroke Vasc Neurol 2016 1 4 154 160 10.1136/svn-2016-000037 28959478 37. Leskinen Y Lehtimaki T Loimaala A Homocysteine and carotid atherosclerosis in chronic renal failure–the confounding effect of renal function Atherosclerosis 2004 175 2 315 323 10.1016/j.atherosclerosis.2004.04.002 15262188 38. Roman MJ Crow MK Lockshin MD Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus Arthritis Rheum 2007 56 10 3412 3419 10.1002/art.22924 17907140 39. McMahon M Skaggs BJ Grossman JM A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus Arthritis Rheumatol (Hoboken, NJ) 2014 66 1 130 139 10.1002/art.38204 40. Rua-Figueroa I Arencibia-Mireles O Elvira M Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study Ann Rheum Dis 2010 69 6 1136 1139 10.1136/ard.2008.104349 19687018 41. Towfighi A Markovic D Ovbiagele B Pronounced association of elevated serum homocysteine with stroke in subgroups of individuals: a nationwide study J Neurol Sci 2010 298 1–2 153 157 10.1016/j.jns.2010.07.013 20810133 42. Daly C Fitzgerald AP O'Callaghan P Homocysteine increases the risk associated with hyperlipidaemia Eur J Cardiovasc Prev Rehabil 2009 16 2 150 155 10.1097/HJR.0b013e32831e1185 19276985 43. Kang JY Park IK Lee JY Use of serum homocysteine to predict cardiovascular disease in Korean men with or without metabolic syndrome J Korean Med Sci 2012 27 5 500 505 10.3346/jkms.2012.27.5.500 22563214 44. Zulli A Hare Dl Buxton BF Black MJ High dietary methionine plus cholesterol exacerbates atherosclerosis formation in the left main coronary artery of rabbits Atherosclerosis 2004 176 1 83 9 10.1016/j.atherosclerosis.2004.05.013 15306178 45. Zhou J Werstuck GH Lhoták S Shi YY Hyperhomocysteinemia induced by methionine supplementation does not independently cause atherosclerosis in C57BL/6J mice FASEB J 2008 22 7 2569 78 10.1096/fj.07-105353 18364397 46. Hofmann MA Lalla E Lu Y Gleason MR Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model J Clin Invest 2001 107 6 675 83 10.1172/JCI10588 11254667